Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71+0.04 (+1.09%)
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Immuneering r&d expenses
Research and development expenses are spending on new products and technology.
Immuneering's R&D Expenses for the twelve months ending Sep 30, 2026 was $54.62M, up 14.6% year over year. For fiscal 2025 it was $42.05M, down 12.3% from the year before. The highest annual figure on record is $47.96M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.05M | -12.3% |
| FY2024 | Dec 31, 2024 | $47.96M | +15.2% |
| FY2023 | Dec 31, 2023 | $41.62M | +14.8% |
| FY2022 | Dec 31, 2022 | $36.27M | +36.6% |
| FY2021 | Dec 31, 2021 | $26.54M | +76.9% |
| FY2020 | Dec 31, 2020 | $15.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $20.72M | +90.7% |
| Q2 FY2026 | Jun 30, 2026 | $14.00M | +33.9% |
| Q1 FY2026 | Mar 31, 2026 | $10.65M | -7.2% |
| Q4 FY2025 | Dec 31, 2025 | $9.25M | -37.7% |
| Q3 FY2025 | Sep 30, 2025 | $10.87M | -3.4% |
| Q2 FY2025 | Jun 30, 2025 | $10.45M | -1.9% |
| Q1 FY2025 | Mar 31, 2025 | $11.47M | +2.4% |
| Q4 FY2024 | Dec 31, 2024 | $14.86M | +24.7% |
| Q3 FY2024 | Sep 30, 2024 | $11.25M | +12.0% |
| Q2 FY2024 | Jun 30, 2024 | $10.65M | +12.7% |
| Q1 FY2024 | Mar 31, 2024 | $11.20M | +9.7% |
| Q4 FY2023 | Dec 31, 2023 | $11.91M | +20.6% |
| Q3 FY2023 | Sep 30, 2023 | $10.05M | +7.3% |
| Q2 FY2023 | Jun 30, 2023 | $9.45M | +18.4% |
| Q1 FY2023 | Mar 31, 2023 | $10.21M | +12.7% |
| Q4 FY2022 | Dec 31, 2022 | $9.87M | +24.2% |
| Q3 FY2022 | Sep 30, 2022 | $9.36M | +50.8% |
| Q2 FY2022 | Jun 30, 2022 | $7.98M | +14.1% |
| Q1 FY2022 | Mar 31, 2022 | $9.06M | +68.0% |
| Q4 FY2021 | Dec 31, 2021 | $7.95M | +62.6% |
| Q3 FY2021 | Sep 30, 2021 | $6.21M | +52.6% |
| Q2 FY2021 | Jun 30, 2021 | $6.99M | +117.1% |
| Q1 FY2021 | Mar 31, 2021 | $5.39M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.89M | – |
| Q3 FY2020 | Sep 30, 2020 | $4.07M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.22M | – |
See a number that looks wrong?